{
    "clinical_study": {
        "@rank": "92466", 
        "arm_group": [
            {
                "arm_group_label": "chemotherapy", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients receive chemotherapy until disease progression or unacceptable toxicity"
            }, 
            {
                "arm_group_label": "Herbal therapy plus chemotherapy", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive herbal therapy plus chemotherapy until disease progression or unacceptable toxicity"
            }
        ], 
        "brief_summary": {
            "textblock": "Teng-Long-Bu-Zhong-Tang (TLBZT) is a modern anti-cancer herbal formula. Experimental studies\n      have confirmed the anti-cancer potential of TLBZT against colorectal cancer. This trial will\n      evaluate the safety and efficacy of TLBZT based herbal therapy in combination with\n      chemotherapy in patients with metastatic colorectal cancer."
        }, 
        "brief_title": "Study of TLBZT Based Herbal Therapy Plus Chemotherapy for Metastatic Colorectal Cancer", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed adenocarcinoma of the colon or rectum with non-resectable\n             metastatic disease;\n\n          -  Ages between 18 and 70 years;\n\n          -  Measurable lesion;\n\n          -  Karnofsky Performance Status \u2265 60%;\n\n          -  Estimated life expectancy of at least 6 months;\n\n          -  Participants have no major organ dysfunction and chemotherapy contraindications:\n             hemoglobin \u226590g/L, N > 1.5\u00d710^9/L, PLT\u2265 100\u00d710^9/L, normal liver and kidney function;\n\n          -  Informed consent from the patient.\n\n        Exclusion Criteria:\n\n          -  Symptomatic brain metastasis;\n\n          -  Adjuvant or neo-adjuvant treatment for non-metastatic disease in past 6 months;\n\n          -  Serious disease of heart, liver, kidney with severe dysfunction;\n\n          -  Serious complications, such as gastrointestinal tract obstruction and hemorrhage;\n\n          -  Pregnancy or breast-feeding women;\n\n          -  Mental or cognitive disorders;\n\n          -  Be participating other drug trials;\n\n          -  Who are allergic to the study drug."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "72", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01975454", 
            "org_study_id": "TCM-mCRC", 
            "secondary_id": "LHYY-11495801300"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "chemotherapy", 
                    "Herbal therapy plus chemotherapy"
                ], 
                "description": "Oxaliplatin (130 mg/m2) was given intravenously (iv) for at least 2 h on day 1; Capecitabine (1000 mg/m2) was given orally, twice daily on days 1-14. Each cycle was 21 days. Cycles were repeated until disease progression or unacceptable toxicity.", 
                "intervention_name": "Chemotherapy", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Oxaliplatin", 
                    "Capecitabine"
                ]
            }, 
            {
                "arm_group_label": "Herbal therapy plus chemotherapy", 
                "description": "TLBZT based herbal decoction administered orally twice a day", 
                "intervention_name": "Herbal therapy", 
                "intervention_type": "Drug", 
                "other_name": "Traditional Chinese Medicine"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Oxaliplatin", 
                "Capecitabine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Metastatic colorectal cancer", 
            "Chemotherapy", 
            "Traditional Chinese Medicine (TCM)", 
            "Teng-Long-Bu-Zhong-Tang"
        ], 
        "lastchanged_date": "October 28, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chongqing", 
                        "country": "China", 
                        "state": "Chongqing", 
                        "zip": "404000"
                    }, 
                    "name": "Chongqing Three Gorges Central Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "state": "Shanghai", 
                        "zip": "200032"
                    }, 
                    "name": "Longhua Hospital"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Pilot Study of Teng-Long-Bu-Zhong-Tang Based Herbal Therapy in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer", 
        "overall_contact": {
            "email": "beearhu@hotmail.com", 
            "last_name": "Bing Hu, MD, PhD", 
            "phone": "86-21-64385700"
        }, 
        "overall_official": [
            {
                "affiliation": "Longhua Hospital, Shanghai University of Traditional Chinese Medicine", 
                "last_name": "Bing Hu, MD, PhD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Chongqing Three Gorges Central Hospital", 
                "last_name": "Gang Li, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Science and Technology Commission of Shanghai Municipality", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression-free survival(PFS)", 
            "safety_issue": "No", 
            "time_frame": "2 months"
        }, 
        "reference": [
            {
                "PMID": "23758730", 
                "citation": "Deng S, Hu B, An HM, Du Q, Xu L, Shen KP, Shi XF, Wei MM, Wu Y. Teng-Long-Bu-Zhong-Tang, a Chinese herbal formula, enhances anticancer effects of 5--Fluorouracil in CT26 colon carcinoma. BMC Complement Altern Med. 2013 Jun 8;13:128. doi: 10.1186/1472-6882-13-128."
            }, 
            {
                "PMID": "21078269", 
                "citation": "Hu B, An HM, Shen KP, Du Q. [Senescence-inducing effects of Chinese herbal medicine Tenglong Buzhong Decoction on human colon carcinoma LS-174-T cells and the mechanism]. Zhong Xi Yi Jie He Xue Bao. 2010 Nov;8(11):1048-52. Chinese."
            }, 
            {
                "PMID": "20550881", 
                "citation": "Hu B, An HM, Shen KP, DU Q. [Effects of Tenglong Buzhong Decoction on proliferation and apoptosis of human colon carcinoma cell line LS174T]. Zhong Xi Yi Jie He Xue Bao. 2010 Jun;8(6):575-80. Chinese. Erratum in: Zhong Xi Yi Jie He Xue Bao. 2011 Mar;9(3):241."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01975454"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "2 months"
            }, 
            {
                "measure": "Symptoms", 
                "safety_issue": "No", 
                "time_frame": "2 months"
            }, 
            {
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "1 month"
            }
        ], 
        "source": "Shanghai University of Traditional Chinese Medicine", 
        "sponsors": {
            "collaborator": {
                "agency": "Chongqing Three Gorges Central Hospital", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Shanghai University of Traditional Chinese Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}